AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone386-462-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$83.94 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
AxoGen (NASDAQ:AXGN) Frequently Asked Questions
What is AxoGen's stock symbol?
AxoGen trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen's earnings last quarter?
AxoGen, Inc (NASDAQ:AXGN) posted its earnings results on Tuesday, August, 6th. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.09. The medical equipment provider had revenue of $26.70 million for the quarter, compared to analysts' expectations of $26.77 million. AxoGen had a negative net margin of 26.91% and a negative return on equity of 16.73%. The business's revenue for the quarter was up 29.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.09) EPS. View AxoGen's Earnings History.
When is AxoGen's next earnings date?
What guidance has AxoGen issued on next quarter's earnings?
AxoGen updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $106-110 million, compared to the consensus revenue estimate of $111.89 million.
What price target have analysts set for AXGN?
6 brokers have issued twelve-month target prices for AxoGen's shares. Their forecasts range from $21.00 to $55.00. On average, they anticipate AxoGen's stock price to reach $31.00 in the next year. This suggests a possible upside of 157.9% from the stock's current price. View Analyst Price Targets for AxoGen.
What is the consensus analysts' recommendation for AxoGen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.
What are Wall Street analysts saying about AxoGen stock?
Here are some recent quotes from research analysts about AxoGen stock:
- 1. BTIG Research analysts commented, "Raise PT to $29 We reiterate our Buy rating and raise our price target to $29 (from $28) following 1Q19 results. 1Q19 results beat both BTIG and Consensus est. with rev. of $23.3M (+34.9% Y/Y) coming in ahead of (~29% implied). Expenses were elevated as one-timers, increasing sales reps, and costs associated with RECON stepped up, but mgmt. expects these costs to moderate through the year. When we upgraded AXGN intra-quarter (here), the crux of our thesis was that improved stability and hiring trends in the sales force following the leadership transition would lead to more consistent execution and allow AXGN to return to improved growth. Thus far, results are playing out as we surmised but we acknowledge it’s still early in the year." (5/10/2019)
- 2. Cantor Fitzgerald analysts commented, "We think AXGN is one of the most compelling growth stories in medtech, with what we believe is sustainable top-line growth of north of 30% for the next two years. We expect utilization to accelerate as favorable clinical and economic data builds and increases surgeon awareness. We would also expect the company to continue to pursue additional market opportunities, as the technology is applicable to nerves across the body. Valuation Summary We value AXGN using a 6x EV/Sales multiple on our 2020 sales estimate to arrive at our 12-month price target of $26." (1/18/2019)
Has AxoGen been receiving favorable news coverage?
Media headlines about AXGN stock have trended somewhat positive on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AxoGen earned a news impact score of 0.6 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for AxoGen.
Are investors shorting AxoGen?
AxoGen saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,800,000 shares, a decrease of 17.4% from the August 30th total of 2,180,000 shares. Based on an average trading volume of 541,900 shares, the short-interest ratio is currently 3.3 days. Approximately 5.1% of the company's shares are sold short. View AxoGen's Current Options Chain.
Who are some of AxoGen's key competitors?
Some companies that are related to AxoGen include Natus Medical (NTUS), Natus Medical (BABY), InMode (INMD), Cutera (CUTR), TransMedics Group (TMDX), BioLife Solutions (BLFS), Zynex (ZYXI), Semler Scientific (SMLR), Viewray (VRAY), Stereotaxis (STXS), BioSig Technologies (BSGM), Rockwell Medical (RMTI), Edap Tms (EDAP), Fonar (FONR) and Second Sight Medical Products (EYES).
What other stocks do shareholders of AxoGen own?
Who are AxoGen's key executives?
AxoGen's management team includes the folowing people:
- Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
- Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
- Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
- Mr. Michael Donovan, VP of Operations (Age 54)
- Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.
Who are AxoGen's major shareholders?
AxoGen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.63%), Pennsylvania Trust Co (0.53%) and Valeo Financial Advisors LLC (0.02%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Daniel Pietrzak, David K Hansen, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Jamie Mark Grooms, Karen L Zaderej, Michael Patrick Donovan, Quentin S Blackford and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.
Which major investors are buying AxoGen stock?
AXGN stock was acquired by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co, Peregrine Capital Management LLC and Valeo Financial Advisors LLC. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, Daniel Pietrzak, Isabelle Billet, Karen L Zaderej and Quentin S Blackford. View Insider Buying and Selling for AxoGen.
How do I buy shares of AxoGen?
Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is AxoGen's stock price today?
One share of AXGN stock can currently be purchased for approximately $12.02.
How big of a company is AxoGen?
AxoGen has a market capitalization of $471.91 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. View Additional Information About AxoGen.
What is AxoGen's official website?
How can I contact AxoGen?
AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]
MarketBeat Community Rating for AxoGen (NASDAQ AXGN)
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
